IntroDuctIon
Since the identification of HIV-1 as the causative agent of the AIDS pandemic, evidence has been accumulating to support the notion that CD8
+ T cells have a central role in restraining HIV/SIV infection in vivo [1] [2] [3] [4] 
. These observations have been reinforced by in vitro assays showing the capacity of CD8 + T cells to inhibit HIV-1 infection of CD4
+ T cells [5] [6] [7] . This has boosted the efforts of the international scientific community to develop an effective HIV-1 vaccine that would induce T-cell responses that could contain the virus, reducing the rate of transmission and the incidence of HIV disease or contributing to protect against infection. However, the failure of Merck's STEP trial showed the limits of the commonly used IFN-γ Elispot surrogate assay 8 . In fact, in the absence of a successful T cell-based vaccine candidate, the definition of what constitutes an effective T-cell response against HIV, and which assay reflects this efficacy most accurately, is still a subject of debate [8] [9] [10] . Much hope has been placed on identifying new correlates of protection in HIV controllers (HIC), a rare population of HIV-infected individuals who can spontaneously control HIV-1 infection to undetectable levels for more than 10 years [11] [12] [13] . Most HIC are characterized by a strong and functional CD8 + T-cell response that very likely contributes to their long-term control of infection 14, 15 . Thus, the CD8 + T-cell response in these HIC currently constitutes one of the most appealing examples of a possible goal for new immune therapies or vaccine strategies 16 . During the last few years, the analysis of CD8 + T-cell response in HIC has revealed different characteristics of efficient HIV-specific CD8 + T cells in HIV infection, including the capacity to proliferate and generate a multifunctional response [17] [18] [19] [20] . However, these characteristics are often revealed only on in vitro activation of cells with optimal or overlapping HIV-1 peptides, and their relevance in the control of infection is uncertain 21, 22 . Our group has developed an assay that assesses the ex vivo capacity of HIV-specific CD8 + T cells to suppress HIV-1 superinfection of autologous CD4 + T cells through cytotoxic activity 20 , this being the ultimate function of CD8 T cells. In fact, the use of ex vivo (nonstimulated) CD8 + T cells, unlike previous assays that used expanded CD8 + T-cell lines, CD8 + T-cell clones or in vitro stimulated primary CD8 + T cells [5] [6] [7] , allows the antiviral potential of the whole untouched pool of HIV-specific CD8 + T cells to be assessed in response to infected relevant target cells, which seems to be highly important to evaluate accurately the antiviral efficacy of circulating HIV-specific CD8 + T cells. Using this assay, it is possible to differentiate between effective anti-HIV CD8 + T-cell responses in HIC and ineffective responses in patients with persistent viremia 20 . We have shown that the enhanced capacity of HIV-specific CD8 + T cells from HIC to inhibit HIV-1 infection requires contact and an MHC matching with target cells, and is caused by the elimination of infected cells rather than by the secretion of soluble antiviral factors (such as β-chemokines or CAF) 20 . We only observed an effect of antiviral factors when working with artificially in vitro activated CD8 + T cells, and this effect was, in any case, very modest 20 . Thus, our study results point to a preponderant role of cytotoxic mechanisms on the highly efficient antiviral response of HIV-specific CD8 + T cells from HIC, which is in agreement with reports by Migueles et al. 18, 19 showing increased lytic granule loading in CD8 + T cells of HIC on contact with infected target cells. Furthermore, we have found that the HIV-suppressive capacity of CD8 + T cells is strongly correlated with the frequency of HIV-specific CD8 + T cells in HIC (but not in viremic individuals), and in particular with the frequency of CD8 + T cells directed against the HIV-1 Gag protein 15 . In fact, the depletion of Gag-specific CD8 + T cells abrogates HIV suppression 15 , suggesting that not all cells have the same anti-HIV potential. This is especially relevant considering that no other differences were observed between CD8 + T cells of different antigen specificity in these experiments (either at the phenotypic level or when other parameters were measured, such as the capacity to secrete cytokines or the potential to proliferate, in response to HIV peptides). The impact of antigen specificity on the capacity of CD8 + T cells to suppress HIV-1 infection may well be due to the different kinetics of antigen presentation on the surface of CD4 + T cells 23 . This underlines the convenience of assessing CD8 + T-cell function in a context closer to that which the cells encounter in vivo, i.e., in response to infected cells rather than to peptide stimulation. In addition, we have shown that the 24 . Therefore, the capacity of CD8 + T cells to suppress HIV-1 infection ex vivo, as measured in our assay, is influenced by the magnitude and quality of the HIV-specific CD8 + T-cell response, the antigen sensitivity of the cells and even the specificity of the response. Each of these attributes is thought to be important for the generation of an efficient CD8 + T-cell response. On the basis of these observations, we proposed that the HIV-suppressive assay may be highly relevant to assess the efficacy of CD8 + T-cell responses generated by vaccine candidates (see Table 1 for the advantages and disadvantages of this protocol) and it complements assays that quantify the frequency of HIV-specific CD8 + T cells 15 
T cells to HIV-1 infection
Reflects the magnitude and quality of the HIV-specific CD8 + T-cell response, the antigen sensitivity of the cells and even the antigenic specificity of the response Dissection of specificities' contribution requires additional experiments involving sorting of cell subpopulations 15, 22 Easy and low-cost adaptability to different HIV-1 strains (tropism, subtype) Choice of viral isolate and infectious dose. The choice of virus depends on the circumstances of the assay (e.g., subtype prevalence within the study population, strain of interest in a vaccine trial and so on) and both primary and lab-adapted strains can be used. We routinely assay the HIV-1-suppressive capacity of CD8 + T cells in parallel against an R5 HIV-1 (BaL) and an X4 HIV-1 (NL4.3). Because the assay is carried out using CD8 + T cells ex vivo, we have not observed a significant contribution of soluble inhibitory factors to HIV-1 suppression (ref. 20 and see above) and the results obtained with both HIV-1 are globally comparable.
For the analysis of HIV-1 suppression capacity on the basis of an HIV-1 p24 ELISA assay, the choice of the infection dose should be one that regularly yields between 100 and 1,000 ng ml − 1 of HIV-1 p24 at the peak of viral replication, using PHA-activated CD4 + T cells from healthy donors (in our hands, using the p24 ELISA Kit from Zeptometrix, a multiplicity of infection (MOI) = 10 − 3.14 of HIV-1 BaL results in levels of infection within these values in > 95% of the cases). A value below 100 ng ml − 1 would not allow a good discrimination between high-quality and low-quality CD8 + T-cell responses, and infections producing above 1,000 ng ml − 1 of HIV-1 p24 in culture supernatants would be too strong even for most high-quality CD8 + T cells. Similarly, when using intracellular HIV-1 Gag determination, the optimal infectious dose is that which results in between 10 and 30% of infected CD4
+ T cells at day 3 after infection. However, with this assay, it is more complicated to regularly obtain the desired level of infection using a single viral dose than with the p24 ELISA assay because of a higher case-to-case variability in the levels of infection at day 3. We normally use two viral doses in parallel (MOI = 10 − 1.15 , 10 − 1.84 ) to ensure that the desired level of infection is achieved.
When working with cells from HIV-1 patients, the peak level of viral replication that is observed on the CD4 + T cells infected in vitro is generally much higher than viral replication at the same time point in control cells (activated but nonsuperinfected, see PROCEDURE). However, sometimes it is not possible to distinguish viral replication of the superinfecting virus (the one inoculated in vitro) from that of the infecting virus (the one that is carried ex vivo by CD4 + T cells from the patient). We have observed that the estimated HIV-1-suppressive capacity of CD8 + T cells might be slightly stronger toward infecting viruses than toward 'consensus' (lab adapted) strains, without significantly altering the results (ref. 15 and unpublished) . Nevertheless, caution should be observed when analyzing such results.
Detection of viral replication: p24 ELISA versus intracellular staining for Gag products. Detection of viral replication is one of the key steps in this protocol. Although different approaches may be used to evaluate the level of infection of the cell cultures, we have chosen to monitor the HIV-1 p24 in culture supernatants by ELISA (Fig. 2a) and to determine the percentage of infected CD4 + T cells by intracellular staining of Gag products (Fig. 2b) . Effectively, these assays are reliable and relatively simple.
Ideally, this protocol should result in a broad range of levels of infection: strong for CD4 + T cells and very weak or even undetectable for cocultures with highly efficient CD8 + T cells (Fig. 2) . We use a kinetic ELISA assay for HIV-1 p24 because it offers a wider range standard curve than do end-point assays, reducing the number of manipulations and dilutions needed to quantify the different culture conditions in a single experiment. Culture supernatants need to be diluted before testing by ELISA (e.g., we often use 1/625 for 7-d postinfection supernatants from CD4 + T cells cultured alone, or 1/5 for supernatants from CD4 + T cells cultured in the presence of highly inhibitory CD8 + T cells). Some experience is required to judge by how much the supernatants should be diluted. The quantification of viral replication by the determination of the number of infected cells (intracellular staining of Gag products) is a convenient method (faster, cheaper and consumes less cells than the p24 ELISA assay) to distinguish CD8 + T cells with weak and strong HIV-1-suppressive capacities. However, it is not as sensitive/quantitative as the p24 ELISA and is probably less well adapted to 'categorize' CD8 + T-cell responses (see Table 2 and Fig. 3 for a comparison of these methods). Perform quality control of flow cytometer (a detailed guideline can be found in ref. 27 ). Transfer fresh blood from peripheral vein into a sterile 50 ml plastic tube and dilute with an equal volume of PBS.  crItIcal step It is recommended to start with at least 10 ml of blood to ensure that enough CD4 + T cells are recovered, especially when blood from HIV-1-infected individuals is analyzed. For healthy individuals, 5 ml of blood should be enough.
2|
Gently add 20 ml diluted blood to 10 ml lymphocyte separation medium in a 50 ml tube.
3|
Centrifuge at 1,200g for 20 min at room temperature (T = 22 °C)  crItIcal step Do not use brake, because a sudden stop will disrupt the density gradient.
4|
Remove the top plasma phase (yellow) through gentle aspiration with a 10 ml pipette and discard (or store for further analysis) 5| Recover the mononuclear cell-containing interface (white) with a 5 ml pipette and transfer to a new 50 ml tube.
6| Add PBS to fill up the tube, and centrifuge at 400g for 10 min at room temperature. Discard the supernatant, loosen the pellet and repeat PBS wash twice.
7|
Resuspend PBMCs in separation buffer and count them in a hemocytometer.
Isolation and activation of cD4
+ t cells • tIMInG 45 min to obtain cD4 + , and 2-3 d for the activation of cD4 + t cells 8| Concentrate PBMCs (typically to 10 7 cells per ml) in chilled separation buffer after centrifugation at 400g for 5 min and perform positive selection of CD4 + cells with an anti-CD4 + antibody coupled to magnetic beads as recommended by the manufacturer (see Experimental design for further discussion).
9| Collect positive fraction from Step 8, count CD4
+ cells and centrifuge cells at 400g for 5 min at room temperature.  crItIcal step Also collect negative fraction for use in Step 12 to purify CD8 + T cells.
10|
Remove supernatant and resuspend cell pellet in activation medium to a final concentration of 10 6 cells per ml. ? troublesHootInG 11| Place cells into a well of a 12-well plate (or of a six-well plate if more than 3 × 10 6 cells are recovered) and culture them for 2-3 d at 37 °C, under 5% CO 2 in a humidified atmosphere.
Isolation and culture of cD8
+ t cells • tIMInG 50 min to obtain cD8 + t cells and 2-3 d of cell culture 12| Concentrate the negative cellular fraction from Step 9 (typically to 10 7 cells per ml) in chilled separation buffer after centrifugation at 400g for 5 min, and perform indirect magnetic cell sorting of untouched CD8 + T cells with a CD8 + T-cell enrichment kit as recommended by the manufacturer (see Experimental design for further discussion).
13| Collect negative fraction, count CD8
+ T cells and centrifuge them at 400g for 5 min at room temperature.  crItIcal step In contrast to CD4 + cells, CD8 + T cells are not magnetically labeled and are recovered in the negative fraction.
14|
Remove supernatant and resuspend cell pellet in culture medium to a final concentration of 10 6 cells per ml.  crItIcal step Do not add cytokines to the culture medium of CD8 + T cells to preserve ex vivo activation status. ? troublesHootInG 15| Place cells into a well of a 12-well plate (or of a six-well plate if more than 3 × 10 6 cells are recovered) and culture in a humidified incubator at 37 °C, 5% CO 2 , during the activation of CD4 + T cells (Step 11). 
+ T cells) or culture medium (for CD8 + T cells).
18|
Count cells with a hemocytometer and adjust concentration to 10 6 cells per ml with suitable medium.  crItIcal step It is important to count cells accurately to allow different experiments to be compared. An automated cell counter is preferable. + t cells using HIV-1 p24 elIsa assay (i) Express the level of secreted p24 (ng ml − 1 ) for each sample at different time points as the mean and standard deviation of triplicate wells (Fig. 2a) . (ii) Calculate the HIV-1-suppressive capacity of CD8 + T cells at the peak of viral replication in the CD4 + T-cell cultures infected in vitro with HIV-1 (typically day 7 or 10) as the log of p24 production lost when CD8 + T cells are present in culture at a 1:1 ratio (see Fig. 2a . 2b ).
19|
HIV suppressive capacity of CD T cells fold decrease in kc -(log % 8 57 for an example). In contrast, CD8 + T cells from HIV-infected individuals can be readily classified by measuring their capacity to suppress HIV infection either by ELISA monitoring of HIV-1 p24 in culture supernatants or by flow cytometry analysis of the percentage of infected CD4 + T cells. The results obtained using these techniques are strongly correlated (Fig. 3) . Highly efficient HIV-specific CD8 + T cells with strong abilities to suppress HIV-1 infection, such as those from HIC, should be able to reduce viral infection by more than 2 logs of p24 when using the ELISA assay, or by more than 1 log of infected cells when using the intracellular assay (Fig. 3, top right corner of the distribution) . However, it is necessary to bear in mind that HIV-1 infection is also generally inhibited to some extent when CD4 + T cells are cultured in the presence of less efficient HIV-specific CD8 + T cells, such as those from HIV-infected viremic individuals 15 (although by less than 1 log of p24 assayed by ELISA or by less than 0.5 log of infected cells with the intracellular assay; Fig. 3 , bottom left corner of the distribution).
